文献速递心外重症与机械循环支持

血型O型心脏移植候选者在新的分配系统下等待时间更长且退出等待名单率更高

Blood type O heart transplant candidates have longer waitlist time and higher delisting under the new allocation system.
PubMed 文献 · J Thorac Cardiovasc Surg · 2022-08-08

该研究纳入2015年4月至2020年12月列出的成人心脏移植候选者,比较O型与非O型候选者的移植生存率和等待名单死亡/恶化,发现O型候选者移植率更低(sHR 0.56)且等待名单死亡/恶化率更高(sHR 1.18),新分配系统下趋势持续,O型供心分配给次级ABO候选者增加(14.5% vs 12.0%),移植后生存相当。

要点

  • O型候选者心脏移植率低于非O型(sHR 0.56,95%CI 0.53-0.58)。
  • O型候选者等待名单死亡/恶化率高于非O型(sHR 1.18,95%CI 1.04-1.34)。
  • 新分配系统下O型供心分配给次级ABO候选者增加(14.5% vs 12.0%,P<.01)。

核心结论

  • 在新分配系统下,O型心脏移植候选者等待时间更长且退出等待名单率更高,需进一步物流考虑以减少血型相关分配不公平。

研究设计与样本

  • 研究纳入2015年4月至2020年12月列出的成人心脏移植候选者,比较O型与非O型候选者,使用竞争风险回归分析。

主要发现

  • O型候选者(n=7509)心脏移植率低于非O型候选者(n=9699)(sHR 0.56,95%CI 0.53-0.58),等待名单死亡/恶化率更高(sHR 1.18,95%CI 1.04-1.34)。
  • 新分配系统下O型候选者移植率仍低(sHR 0.58,95%CI 0.54-0.62),死亡/临床恶化率更高(sHR 1.27,95%CI 1.02-1.60)。
  • 在高状态(1、2或3)列出的候选者中,O型移植率更低(sHR 0.69,95%CI 0.63-0.75),死亡/恶化率更高(sHR 1.61,95%CI 1.16-2.22)。
  • 在状态3列出的候选者中,有持久左心室辅助装置者死亡/恶化sHR 1.57(95%CI 0.58-4.29),无左心室辅助装置者sHR 3.79(95%CI 1.28-11.2)。
  • 新系统下O型供心分配给次级ABO候选者增加(14.5% vs 12.0%,P<.01);O型与非O型受者移植后生存相当(log-rank P=.07)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Prior studies have examined the effect of blood type on heart transplantation (HTx) waitlist outcomes in cohorts through 2015. We aim to analyze the effect of blood type on contemporary waitlist outcomes with a new allocation system focus. METHODS: Adults listed for HTx between April 2015 and December 2020 were included. Survival to HTx and waitlist death/deterioration was compared between type O and non-type O candidates using competing risks regression. Donor/recipient ABO compatibility trends were further investigated. RESULTS: Candidates with blood type O (n = 7509) underwent HTx less frequently than candidates with blood type other than type O (n = 9699) (subhazard ratio [sHR], 0.56; 95% CI, 0.53-0.58) with higher rates of waitlist death/deterioration (sHR, 1.18; 95% CI, 1.04-1.34). Subgroup analyses demonstrated persistence of this trend under the new donor heart allocation system (HTx: sHR, 0.58; 95% CI, 0.54-0.62; death/clinical deterioration: sHR, 1.27; 95% CI, 1.02-1.60), especially among those listed at high status (1, 2, or 3) (HTx: sHR, 0.69; 95% CI, 0.63-0.75; death/deterioration: sHR, 1.61; 95% CI, 1.16-2.22). Among those listed at status 3, waitlist death/deterioration was modified by presence of a durable left ventricular assist device (left ventricular assist device: sHR, 1.57; 95% CI, 0.58-4.29; no left ventricular assist device: sHR, 3.79; 95% CI, 1.28-11.2). Type O donor heart allocation to secondary ABO candidates increased in the new system (14.5% vs 12.0%; P < .01); post-HTx survival remained comparable between recipients with blood type O and non-type O (log-rank P = .07). CONCLUSIONS: Further logistical considerations are warranted to minimize allocation inequity regarding blood type under the new allocation system.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Eapen S, Nordan T, Critsinelis AC, et al. Blood type O heart transplant candidates have longer waitlist time and higher delisting under the new allocation system. J Thorac Cardiovasc Surg. 2022. PMID: 36100474. doi:10.1016/j.jtcvs.2022.07.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。